Adam L. Holtzman, M.D.

Closed for Enrollment

• DART 2.0: ctHPV-DNA Informed De-Escalated Adjuvant and Definitive Radiation Therapy (GMROR2271) Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

  The primary goal of this study is to prospectively incorporate ctHPVDNA in combination with clinical and pathologic factors to appropriately select patients for treatment intensity.